Private equity firm ChrysCapital has completed its acquisition of a controlling 70.68% stake in Novartis India Ltd. (NIL), marking a significant milestone in India’s pharmaceutical sector. Alongside the completion of the deal, the company has appointed former Alkem Laboratories executive Dr. Vikas Gupta as its new Managing Director and Chief Executive Officer, ushering in a new chapter for the company following its separation from Swiss pharmaceutical giant Novartis AG.
The transaction, first announced in February 2026, is valued at approximately ₹1,446 crore and represents ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical industry.
A New Era for Novartis India
With the acquisition now complete, Novartis India will begin operating under new ownership after decades as part of Novartis AG. The company has announced that it will adopt a new corporate identity and brand name, reflecting its transition into an independent, India-focused pharmaceutical business.
ChrysCapital said it plans to transform the company into a leading domestic branded formulations platform, leveraging its healthcare investment experience and operational expertise rather than treating the business as a standalone carve-out asset.
Dr. Vikas Gupta to Lead Growth Strategy
To spearhead this transformation, ChrysCapital has appointed Dr. Vikas Gupta as Managing Director and CEO.
Dr. Gupta previously served as the Chief Executive Officer of Alkem Laboratories, one of India’s leading pharmaceutical companies. With more than two decades of experience in the pharmaceutical industry, he has worked across multiple therapeutic areas, including acute care, chronic diseases, respiratory medicine, and metabolic disorders.
A medical graduate from the University College of Medical Sciences, Delhi University, Dr. Gupta is also recognized for leading business transformation initiatives and driving commercial growth across domestic and international markets.
Strengthening the Leadership Team
In addition to Dr. Gupta’s appointment, the company has strengthened its board by inducting:
- Ramesh Ramadurai as Independent Director and Chairperson
- Suchita Sharma as Independent Director
- Shashank Sinha as Independent Director
The refreshed leadership team is expected to guide the company through its transition while supporting long-term strategic growth.
ChrysCapital’s Vision for the Business
ChrysCapital believes India’s pharmaceutical market offers significant long-term growth opportunities, driven by rising healthcare demand, expanding insurance coverage, and increasing access to medicines.
Rather than maintaining Novartis India solely as a distribution business, the investment firm plans to strengthen its branded formulations portfolio, expand its product offerings, and build a more competitive pharmaceutical company focused on the Indian market.
The acquisition aligns with ChrysCapital’s broader strategy of investing in high-growth sectors such as healthcare and life sciences, where it has built considerable expertise over the past two decades.
What the Deal Means for India’s Pharma Sector
The acquisition signals continued investor confidence in India’s pharmaceutical industry, which remains one of the fastest-growing healthcare markets globally.
Private equity firms have increasingly shown interest in pharmaceutical manufacturing, branded medicines, and healthcare services as demand continues to rise both domestically and internationally. ChrysCapital’s investment is expected to provide Novartis India with additional capital, strategic guidance, and operational support to accelerate growth in this competitive landscape.
Looking Ahead
With the acquisition complete and a new leadership team in place, Novartis India is preparing to enter its next phase as an independently managed pharmaceutical company.
The combination of ChrysCapital’s investment expertise and Dr. Vikas Gupta’s industry experience is expected to help the company strengthen its market position, expand its branded medicines portfolio, and pursue sustainable long-term growth. As India’s healthcare sector continues to evolve, the newly restructured company aims to emerge as a stronger player in the country’s pharmaceutical market.
